Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis

Mouhamad Nasser, Julie Traclet, Vincent Cottin

Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017
Journal Issue: January

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Mouhamad Nasser, Julie Traclet, Vincent Cottin. Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis. ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Chemotherapy in patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018



Pulmonary Langerhans' cell histiocytosis
Source: Respipedia Article
Year: 2016

Cladribine improves lung cysts and pulmonary function in a child with histiocytosis
Source: Eur Respir J 2015; 45: 831-833
Year: 2015


Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020


Treatment of pulmonary Langerhans cell histiocytosis with multifocal involvement with vinblastine, prednisolon, mercaptopurine
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010


Lung transplantation for pulmonary Langerhans‘ cell histiocytosis
Source: Eur Respir J 2005; 26: Suppl. 49, 635s
Year: 2005

How I manage pulmonary Langerhans cell histiocytosis
Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017
Year: 2017



Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019



Pulmonary Langerhans‘ cell histiocytosis
Source: Eur Respir J 2006; 28: Suppl. 50, 826s
Year: 2006

Pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2008 - PG5 - Interstitial lung diseases: selected orphan diseases
Year: 2008



Paediatric pulmonary Langerhans cell histiocytosis
Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020
Year: 2020



Pneumothorax in pulmonary langerhans cell histiocytosis (PLCH)
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018




Multisystemic Langerhans cell histiocytosis unresponsive to aggressive chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 383s
Year: 2006

Pneumothorax in patients with Langerhans cell histiocytosis
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017

Pulmonary Langerhans' cell histiocytosis
Source: Eur Respir Mon; 2009: 46: 155–175
Year: 2009

Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis
Source: Eur Respir Mon 2012; 57: 161-165
Year: 2012


Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012

Genetic landscape of pulmonary langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018

Langerhans cell histiocytosis: is it an ILD?
Source: Virtual Congress 2021 – Interstitial lung diseases
Year: 2021